Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics (ANTX) reported an insider equity grant. Director Patricia A. Martin acquired 3,274 shares of common stock on 10/10/2025, issued in lieu of cash compensation under the company’s non-employee director compensation policy. The filing states these shares vest immediately. After this transaction, Martin beneficially owns 13,255 shares, held directly. The transaction price is shown as $0, reflecting a stock award rather than an open-market purchase.
AN2 Therapeutics (ANTX) reported interim results showing continued clinical progress and a tighter cash position. Total cash, cash equivalents and investments were $71.2 million as of June 30, 2025, with cash and cash equivalents of $18.22 million and short- and long-term investments of $44.70 million and $8.30 million, respectively. Management believes these resources are sufficient to fund the company’s current operating plan for at least 12 months.
The company recorded a $17.1 million net loss for the six months ended June 30, 2025 (versus $31.1 million in the comparable 2024 period), driven by research and development and general and administrative expenses. AN2 advanced AN2-502998 into Phase 1 start-up activities and completed dosing of the first single ascending dose cohort (reported events in May and August 2025). Funding arrangements include government and foundation awards, but a NIAID contract was reduced by $9.0 million to a cumulative $9.3 million commitment. The company continues to rely on external financing and grants while it advances multiple boron-chemistry programs.
AN2 Therapeutics reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The filing states that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference in other filings except by specific reference. The report is dated August 12, 2025 and is signed by Chief Executive Officer Eric Easom.
AN2 Therapeutics, Inc. (ANTX) filed a Form 4 reporting a routine equity grant to director Kabeer Aziz. On 07/10/2025 Mr. Aziz received 11,875 shares of common stock issued in lieu of cash compensation under the company’s non-employee director compensation policy. Because the award was compensation, the shares were priced at $0.00 and vested immediately.
Following the grant, Mr. Aziz now directly holds 30,552 shares. He also has indirect beneficial ownership—through Adjuvant Global Health Technology Fund, L.P. (1,995,958 shares) and Adjuvant Global Health Technology Fund DE, L.P. (377,542 shares)—bringing total reported influence to roughly 2.404 million shares. However, the filing notes that voting and dispositive power is shared with the funds’ general partners and that beneficial ownership is disclaimed except for pecuniary interest.
No derivative securities, options, sales, or open-market purchases were reported, and no cash was exchanged. The transaction appears purely compensatory and does not signal a deliberate insider buy or sell decision. Investors typically view such awards as neutral unless the size represents a material percentage of total shares outstanding, which the filing does not disclose.